Stock Track | Burning Rock Biotech Soars 7.61% Intraday as Breast Cancer Diagnostic Kit Enters Priority Review

Stock Track

01/26

Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.

The surge came after the company announced that its self-developed "OncoScreen® BCMatch Tissue Kit," a breast cancer next-generation sequencing companion diagnostic kit, has entered the Priority Review Channel of China's Center for Medical Device Evaluation. This marks the first breast cancer NGS CDx kit in China to enter this expedited review process, which is expected to accelerate its domestic approval timeline.

This regulatory milestone represents significant progress for Burning Rock Biotech's oncology diagnostics portfolio and could potentially enhance the company's market position in China's growing precision medicine landscape.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1136963079"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136963079\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136963079?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136963079","market":"nz","top_or_hot":-1,"title":"Stock Track | Burning Rock Biotech Soars 7.61% Intraday as Breast Cancer Diagnostic Kit Enters Priority Review","media":"Stock Track","content":"<p>Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.</p><p>The surge came after the company announced that its self-developed \"OncoScreen® BCMatch Tissue Kit,\" a breast cancer next-generation sequencing companion diagnostic kit, has entered the Priority Review Channel of China's Center for Medical Device Evaluation. This marks the first breast cancer NGS CDx kit in China to enter this expedited review process, which is expected to accelerate its domestic approval timeline.</p><p>This regulatory milestone represents significant progress for Burning Rock Biotech's oncology diagnostics portfolio and could potentially enhance the company's market position in China's growing precision medicine landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Biotech Soars 7.61% Intraday as Breast Cancer Diagnostic Kit Enters Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Biotech Soars 7.61% Intraday as Breast Cancer Diagnostic Kit Enters Priority Review\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-01-26 23:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.</p><p>The surge came after the company announced that its self-developed \"OncoScreen® BCMatch Tissue Kit,\" a breast cancer next-generation sequencing companion diagnostic kit, has entered the Priority Review Channel of China's Center for Medical Device Evaluation. This marks the first breast cancer NGS CDx kit in China to enter this expedited review process, which is expected to accelerate its domestic approval timeline.</p><p>This regulatory milestone represents significant progress for Burning Rock Biotech's oncology diagnostics portfolio and could potentially enhance the company's market position in China's growing precision medicine landscape.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石醫學","start_time":0,"source_url":"","article_id":"1136963079","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136963079","pubTimestamp":1769440587,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.The surge came after the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"个股追踪|燃石生物盘中大涨7.61%乳腺癌诊断试剂盒进入优先审评","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Burning Rock Biotech Limited's stock soared 7.61% during intraday trading on Monday, following positive regulatory news for the company's diagnostic pipeline.The surge came after the company announced that its self-developed \"OncoScreen® BCMatch Tissue Kit,\" a breast cancer next-generation sequencing companion diagnostic kit, has entered the Priority Review Channel of China's Center for Medical Device Evaluation. This marks the first breast cancer NGS CDx kit in China to enter this expedited review process, which is expected to accelerate its domestic approval timeline.This regulatory milestone represents significant progress for Burning Rock Biotech's oncology diagnostics portfolio and could potentially enhance the company's market position in China's growing precision medicine landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}